| Literature DB >> 20685205 |
Thomas V Johnson1, Natalie D Bull, Keith R Martin.
Abstract
Glaucoma is a progressive optic neuropathy and a major cause of visual impairment worldwide. Neuroprotective therapies for glaucoma aim to ameliorate retinal ganglion cell degeneration through direct or indirect action on these neurons. Neurotrophic factor (NTF) delivery is a key target for the development of potential neuroprotective glaucoma treatments. This article will critically summarize the evidence that NTF deprivation and/or dysfunction plays a role in the pathogenesis of glaucoma. Experimental support for the neuroprotective potential of NTF supplementation in animal models of glaucoma will be reviewed, in particular for brain-derived neurotrophic factor, ciliary neurotrophic factor, and glial cell line-derived neurotrophic factor. Finally, the challenges of clinical translation will be considered with an emphasis on the most promising NTF delivery strategies including slow-release drug delivery, gene therapy, and cell transplantation.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20685205 DOI: 10.1016/j.exer.2010.05.016
Source DB: PubMed Journal: Exp Eye Res ISSN: 0014-4835 Impact factor: 3.467